These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 30655019)

  • 1. Chylomicronemia: Differences between familial chylomicronemia syndrome and multifactorial chylomicronemia.
    Paquette M; Bernard S; Hegele RA; Baass A
    Atherosclerosis; 2019 Apr; 283():137-142. PubMed ID: 30655019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rare Variants in Triglycerides-Related Genes Increase Pancreatitis Risk in Multifactorial Chylomicronemia Syndrome.
    Paquette M; Amyot J; Fantino M; Baass A; Bernard S
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3473-e3482. PubMed ID: 34019660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the chylomicron-TG to VLDL-TG ratio for type I hyperlipoproteinemia diagnostic.
    Rioja J; Ariza MJ; García-Casares N; Coca-Prieto I; Arrobas T; Muñiz-Grijalvo O; Mangas A; Ibarretxe D; Sánchez-Chaparro MÁ; Valdivielso P
    Eur J Clin Invest; 2020 Dec; 50(12):e13345. PubMed ID: 32649781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analyses of familial chylomicronemia syndrome in Pereira, Colombia 2010-2020: a cross-sectional study.
    Rodriguez FH; Estrada JM; Quintero HMA; Nogueira JP; Porras-Hurtado GL
    Lipids Health Dis; 2023 Mar; 22(1):43. PubMed ID: 36978188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissection of Clinical and Gene Expression Signatures of Familial versus Multifactorial Chylomicronemia.
    Tremblay K; Gaudet D; Khoury E; Brisson D
    J Endocr Soc; 2020 Jun; 4(6):bvaa056. PubMed ID: 32537545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-Alcoholic Fatty Liver in Patients with Chylomicronemia.
    Maltais M; Brisson D; Gaudet D
    J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33572376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges in familial chylomicronemia syndrome diagnosis and management across Latin American countries: An expert panel discussion.
    Santos RD; Lorenzatti A; Corral P; Nogueira JP; Cafferata AM; Aimone D; Lourenço CM; Izar MC; Lima JG; Lottenberg AM; Alonso R; Garay K; Morales AR; Vargas-Uricoechea H; Peña CAC; Roman-González A
    J Clin Lipidol; 2021; 15(5):620-624. PubMed ID: 34920815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Familial chylomicronemia syndrome: pediatric experience in Argentina].
    Araujo MB; Eiberman G; Etcheverry N; Pacheco G
    Arch Argent Pediatr; 2022 Jun; 120(3):e123-e127. PubMed ID: 35533124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Familial Chylomicronemia Syndrome (FCS): Recent Data on Diagnosis and Treatment.
    Gallo A; Béliard S; D'Erasmo L; Bruckert E
    Curr Atheroscler Rep; 2020 Aug; 22(11):63. PubMed ID: 32852651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 10-Year Comparative Follow-up of Familial versus Multifactorial Chylomicronemia Syndromes.
    Belhassen M; Van Ganse E; Nolin M; Bérard M; Bada H; Bruckert E; Krempf M; Rebours V; Valero R; Moulin P
    J Clin Endocrinol Metab; 2021 Mar; 106(3):e1332-e1342. PubMed ID: 33221907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Familial chylomicronemia syndrome: case reports of siblings with deletions of the GPIHBP1 gene.
    Kim KY; Heo YJ; Ko JM; Lee YA; Shin CH; Ki CS; Lee YJ
    BMC Endocr Disord; 2024 Apr; 24(1):47. PubMed ID: 38622573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Qualitative development of the PROMIS Profile v1.0-Familial Chylomicronemia Syndrome (FCS) 28.
    Kaiser K; Fox RS; Perschon C; Vera-Llonch M; Alonso J; Cubells L; Cella D
    Qual Life Res; 2023 Feb; 32(2):605-614. PubMed ID: 36310187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of lipoprotein lipase activity measurement in the diagnosis of familial chylomicronemia syndrome.
    Rioja J; Ariza MJ; Benítez-Toledo MJ; Espíldora-Hernández J; Coca-Prieto I; Arrobas-Velilla T; Camacho A; Olivecrona G; Sánchez-Chaparro MÁ; Valdivielso P
    J Clin Lipidol; 2023; 17(2):272-280. PubMed ID: 36813655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Familial chylomicronemia and multifactorial chylomicronemia.
    Muñiz-Grijalvo O; Diaz-Diaz JL
    Clin Investig Arterioscler; 2021 May; 33 Suppl 2():56-62. PubMed ID: 34006355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute pancreatitis risk in multifactorial chylomicronemia syndrome depends on the molecular cause of severe hypertriglyceridemia.
    Guay SP; Paquette M; Taschereau A; Girard L; Desgagné V; Bouchard L; Bernard S; Baass A
    Atherosclerosis; 2024 May; 392():117489. PubMed ID: 38448342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-prandial analysis of fluctuations in the platelet count and platelet function in patients with the familial chylomicronemia syndrome.
    Larouche M; Brisson D; Morissette MC; Gaudet D
    Orphanet J Rare Dis; 2023 Jun; 18(1):167. PubMed ID: 37370069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Volanesorsen for treatment of familial chylomicronemia syndrome.
    Lazarte J; Hegele RA
    Expert Rev Cardiovasc Ther; 2021 Aug; 19(8):685-693. PubMed ID: 34261380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of a pregnant patient with chylomicronemia from a novel mutation in GPIHBP1: a case report.
    Lin MH; Tian XH; Hao XL; Fei H; Yin JL; Yan DD; Li T
    BMC Pregnancy Childbirth; 2020 May; 20(1):272. PubMed ID: 32375710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreatitis risk in genetic subtypes of multifactorial chylomicronemia syndrome.
    Berberich AJ; Hegele RA
    Atherosclerosis; 2024 May; 392():117528. PubMed ID: 38594114
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety and efficacy of therapies for chylomicronemia.
    Shamsudeen I; Hegele RA
    Expert Rev Clin Pharmacol; 2022 Apr; 15(4):395-405. PubMed ID: 35762447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.